| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Qiang Qiang, Loren Skudder-Hill, Tomoko Toyota, Zhe Huang, Wenshi Wei, Hiroaki Adach. CSF 14-3-3 zeta(ζ) isoform is associated with tau pathology and cognitive decline in Alzheimer's disease. Journal of the neurological sciences. vol 457. 2024-01-09. PMID:38194803. |
the present study examined the cerebrospinal fluid (csf) 14-3-3ζ levels of 719 participants from the alzheimer's disease neuroimaging initiative (adni), including cognitively normal (cn) participants, patients with mild cognitive impairment (mci) and patients with ad dementia, and aimed to identify whether csf 14-3-3ζ is associated with tau pathology. |
2024-01-09 |
2024-01-13 |
human |
| Lannah S Abasi, Nesreen Elathram, Manasi Movva, Amar Deep, Kevin D Corbett, Galia T Debelouchin. Phosphorylation regulates tau's phase separation behavior and interactions with chromatin. bioRxiv : the preprint server for biology. 2024-01-08. PMID:38187700. |
tau is a microtubule-associated protein often found in neurofibrillary tangles (nfts) in the brains of patients with alzheimer's disease (ad). |
2024-01-08 |
2024-01-10 |
Not clear |
| Kevin P Kotredes, Ravi S Pandey, Scott Persohn, Kierra Elderidge, Charles P Burton, Ethan W Miner, Kathryn A Haynes, Diogo Francisco S Santos, Sean-Paul Williams, Nicholas Heaton, Cynthia M Ingraham, Christopher Lloyd, Dylan Garceau, Rita O'Rourke, Sarah Herrick, Claudia Rangel-Barajas, Surendra Maharjan, Nian Wang, Michael Sasner, Bruce T Lamb, Paul R Territo, Stacey J Sukoff Rizzo, Gregory W Carter, Gareth R Howell, Adrian L Obla. Characterizing Molecular and Synaptic Signatures in mouse models of Late-Onset Alzheimer's Disease Independent of Amyloid and Tau Pathology. bioRxiv : the preprint server for biology. 2024-01-08. PMID:38187716. |
characterizing molecular and synaptic signatures in mouse models of late-onset alzheimer's disease independent of amyloid and tau pathology. |
2024-01-08 |
2024-01-10 |
mouse |
| Samantha C Burnham, Leonardo Iaccarino, Michael J Pontecorvo, Adam S Fleisher, Ming Lu, Emily C Collins, Michael D Devou. A review of the flortaucipir literature for positron emission tomography imaging of tau neurofibrillary tangles. Brain communications. vol 6. issue 1. 2024-01-08. PMID:38187878. |
alzheimer's disease is defined by the presence of β-amyloid plaques and neurofibrillary tau tangles potentially preceding clinical symptoms by many years. |
2024-01-08 |
2024-01-10 |
Not clear |
| Lydia Jiang, Jessica Robin, Nathanael Shing, Negar Mazloum-Farzaghi, Natalia Ladyka-Wojcik, Niroja Balakumar, Nicole D Anderson, Jennifer D Ryan, Morgan D Barense, Rosanna K Olse. Impaired perceptual discrimination of complex objects in older adults at risk for dementia. Hippocampus. 2024-01-08. PMID:38189156. |
tau pathology accumulates in the perirhinal cortex (prc) of the medial temporal lobe (mtl) during the earliest stages of the alzheimer's disease (ad), appearing decades before clinical diagnosis. |
2024-01-08 |
2024-01-10 |
Not clear |
| Ping Wang, Audrey Lynn, Kristy Miskimen, Yeunjoo E Song, Thomas Wisniewski, Mark Cohen, Brian S Appleby, Jiri G Safar, Jonathan L Haine. Genome-wide association studies identify novel loci in rapidly progressive Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2024-01-07. PMID:38184787. |
recent data suggest that distinct prion-like amyloid beta and tau strains are associated with rapidly progressive alzheimer's disease (rpad). |
2024-01-07 |
2024-01-09 |
Not clear |
| Juan Lantero-Rodriguez, Laia Montoliu-Gaya, Andrea L Benedet, Agathe Vrillon, Julien Dumurgier, Emmanuel Cognat, Wagner S Brum, Nesrine Rahmouni, Jenna Stevenson, Stijn Servaes, Joseph Therriault, Bruno Becker, Gunnar Brinkmalm, Anniina Snellman, Hanna Huber, Hlin Kvartsberg, Nicholas J Ashton, Henrik Zetterberg, Claire Paquet, Pedro Rosa-Neto, Kaj Blenno. CSF p-tau205: a biomarker of tau pathology in Alzheimer's disease. Acta neuropathologica. vol 147. issue 1. 2024-01-06. PMID:38184490. |
csf p-tau205: a biomarker of tau pathology in alzheimer's disease. |
2024-01-06 |
2024-01-09 |
human |
| Juan Lantero-Rodriguez, Laia Montoliu-Gaya, Andrea L Benedet, Agathe Vrillon, Julien Dumurgier, Emmanuel Cognat, Wagner S Brum, Nesrine Rahmouni, Jenna Stevenson, Stijn Servaes, Joseph Therriault, Bruno Becker, Gunnar Brinkmalm, Anniina Snellman, Hanna Huber, Hlin Kvartsberg, Nicholas J Ashton, Henrik Zetterberg, Claire Paquet, Pedro Rosa-Neto, Kaj Blenno. CSF p-tau205: a biomarker of tau pathology in Alzheimer's disease. Acta neuropathologica. vol 147. issue 1. 2024-01-06. PMID:38184490. |
post-mortem staging of alzheimer's disease (ad) neurofibrillary pathology is commonly performed by immunohistochemistry using at8 antibody for phosphorylated tau (p-tau) at positions 202/205. |
2024-01-06 |
2024-01-09 |
human |
| Pia Kivisäkk, Hadia A Fatima, Danielle S Cahoon, Brunah Otieno, Leena Chacko, Farnaz Minooei, Catherine Demos, Martin Stengelin, George Sigal, Jacob Wohlstadter, Steven E Arnol. Clinical evaluation of a novel plasma pTau217 electrochemiluminescence immunoassay in Alzheimer's disease. Scientific reports. vol 14. issue 1. 2024-01-05. PMID:38182740. |
a growing literature suggests that plasma levels of tau phosphorylated at amino acid 217 (ptau217) performs similarly to cerebrospinal fluid (csf) biomarkers and pet imaging to detect amyloid pathology and to provide diagnostic and prognostic information in alzheimer's disease (ad), but a significant limiting factor thus far has been a lack of widely available immunoassays. |
2024-01-05 |
2024-01-08 |
Not clear |
| Muhammad Ayaz, Osama F Mosa, Asif Nawaz, Alashary Adam Eisa Hamdoon, Modawy Elnour Modawy Elkhalifa, Abdul Sadiq, Farhat Ullah, Alshebli Ahmed, Atul Kabra, Haroon Khan, H C Ananda Murth. Neuroprotective potentials of Lead phytochemicals against Alzheimer's disease with focus on oxidative stress-mediated signaling pathways: Pharmacokinetic challenges, target specificity, clinical trials and future perspectives. Phytomedicine : international journal of phytotherapy and phytopharmacology. vol 124. 2024-01-05. PMID:38181530. |
alzheimer's diseases (ad) and dementia are among the highly prevalent neurological disorders characterized by deposition of beta amyloid (aβ) plaques, dense deposits of highly phosphorylated tau proteins, insufficiency of acetylcholine (ach) and imbalance in glutamatergic system. |
2024-01-05 |
2024-01-08 |
Not clear |
| Daniel Ruiz-Gabarre, Laura Vallés-Saiz, Almudena Carnero-Espejo, Isidro Ferrer, Félix Hernández, Ramon Garcia-Escudero, Jesús Ávila, Vega García-Escuder. Intron retention as a productive mechanism in human MAPT: RNA species generated by retention of intron 3. EBioMedicine. vol 100. 2024-01-05. PMID:38181704. |
tau is essential for several physiological functions and associated with pathological processes, including alzheimer's disease (ad). |
2024-01-05 |
2024-01-08 |
human |
| George Anderso. A More Holistic Perspective of Alzheimer's Disease: Roles of Gut Microbiome, Adipocytes, HPA Axis, Melatonergic Pathway and Astrocyte Mitochondria in the Emergence of Autoimmunity. Frontiers in bioscience (Landmark edition). vol 28. issue 12. 2024-01-05. PMID:38179773. |
for 40 years, alzheimer's disease pathophysiology has focused on two culprits, amyloid-β induced plaques and hyperphosphorylated tau associated tangles, with no significant treatment advance. |
2024-01-05 |
2024-01-07 |
Not clear |
| Mónica Rosselli, Idaly Vélez Uribe, Emily Ahne, Layaly Shihade. Culture, Ethnicity, and Level of Education in Alzheimer's Disease. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. vol 19. issue 1. 2024-01-04. PMID:38176794. |
alzheimer's disease (ad) is the most frequent cause of dementia, where the abnormal accumulation of beta-amyloid (aβ) and tau lead to neurodegeneration as well as loss of cognitive, behavioral, and functional abilities. |
2024-01-04 |
2024-01-07 |
Not clear |
| Todd E Gold. Disease-Modifying Therapies for Alzheimer's Disease: More Questions than Answers. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. vol 19. issue 1. 2024-01-04. PMID:38176791. |
scientific advances over the last four decades have steadily infused the alzheimer's disease (ad) field with great optimism that therapies targeting aβ, amyloid, tau, and innate immune activation states in the brain would provide disease modification. |
2024-01-04 |
2024-01-07 |
Not clear |
| Ana Rita Agra Almeida Quadros, Zhaozhi Li, Xue Wang, I Sandra Ndayambaje, Sandeep Aryal, Nandini Ramesh, Matthew Nolan, Rojashree Jayakumar, Yi Han, Hannah Stillman, Corey Aguilar, Hayden J Wheeler, Theresa Connors, Jone Lopez-Erauskin, Michael W Baughn, Ze'ev Melamed, Melinda S Beccari, Laura Olmedo Martínez, Michael Canori, Chao-Zong Lee, Laura Moran, Isabelle Draper, Alan S Kopin, Derek H Oakley, Dennis W Dickson, Don W Cleveland, Bradley T Hyman, Sudeshna Das, Nilüfer Ertekin-Taner, Clotilde Lagier-Tourenn. Cryptic splicing of stathmin-2 and UNC13A mRNAs is a pathological hallmark of TDP-43-associated Alzheimer's disease. Acta neuropathologica. vol 147. issue 1. 2024-01-04. PMID:38175301. |
here, we identify both stmn2 and unc13a cryptic exons in alzheimer's disease patients, that correlate with tdp-43 pathology burden, but not with amyloid-β or tau deposits. |
2024-01-04 |
2024-01-06 |
Not clear |
| Daniel C Xu, Hanna Sas-Nowosielska, Greg Donahue, Hua Huang, Naemeh Pourshafie, Charly R Good, Shelley L Berge. Histone acetylation in an Alzheimer's disease cell model promotes homeostatic amyloid-reducing pathways. Acta neuropathologica communications. vol 12. issue 1. 2024-01-03. PMID:38167174. |
alzheimer's disease (ad) is a disorder characterized by cognitive decline, neurodegeneration, and accumulation of amyloid plaques and tau neurofibrillary tangles in the brain. |
2024-01-03 |
2024-01-06 |
Not clear |
| Qinggang Fu, Bixiang Zhang, Xiaoping Chen, Liang Ch. Liquid-liquid phase separation in Alzheimer's disease. Journal of molecular medicine (Berlin, Germany). 2024-01-03. PMID:38167731. |
the pathological aggregation and misfolding of tau and amyloid-β play a key role in alzheimer's disease (ad). |
2024-01-03 |
2024-01-06 |
human |
| Valeria Melissa García-Cruz, Clorinda Aria. Palmitic Acid Induces Posttranslational Modifications of Tau Protein in Alzheimer's Disease-Related Epitopes and Increases Intraneuronal Tau Levels. Molecular neurobiology. 2024-01-03. PMID:38167971. |
palmitic acid induces posttranslational modifications of tau protein in alzheimer's disease-related epitopes and increases intraneuronal tau levels. |
2024-01-03 |
2024-01-06 |
human |
| Pallabi Sil Paul, Tark Patel, Jae-Young Cho, Allan Yarahmady, Aria Khalili, Valentyna Semenchenko, Holger Wille, Marianna Kulka, Sue-Ann Mok, Satyabrata Ka. Native PLGA nanoparticles attenuate Aβ-seed induced tau aggregation under in vitro conditions: potential implication in Alzheimer's disease pathology. Scientific reports. vol 14. issue 1. 2024-01-03. PMID:38167993. |
native plga nanoparticles attenuate aβ-seed induced tau aggregation under in vitro conditions: potential implication in alzheimer's disease pathology. |
2024-01-03 |
2024-01-06 |
Not clear |
| Pallabi Sil Paul, Tark Patel, Jae-Young Cho, Allan Yarahmady, Aria Khalili, Valentyna Semenchenko, Holger Wille, Marianna Kulka, Sue-Ann Mok, Satyabrata Ka. Native PLGA nanoparticles attenuate Aβ-seed induced tau aggregation under in vitro conditions: potential implication in Alzheimer's disease pathology. Scientific reports. vol 14. issue 1. 2024-01-03. PMID:38167993. |
evidence suggests that beta-amyloid (aβ)-induced phosphorylation/aggregation of tau protein plays a critical role in the degeneration of neurons and development of alzheimer's disease (ad), the most common cause of dementia affecting the elderly population. |
2024-01-03 |
2024-01-06 |
Not clear |